[CLAIMS]

[Claim 1]

Use of an effective amount of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof in the manufacture of a pharmaceutical composition for treating an LSD1-related disease or disorder in a patient in need, wherein the pharmaceutical composition is to be administered to the patient on an administration schedule comprising daily dosing for one week, followed by a resting period of one week.

[Claim 2]

The use of Claim 1, wherein the administration schedule is based on a 2-week cycle, and the cycle is performed once or repeated two or more times.

[Claim 3]

The use of Claim 1, wherein 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof is to be administered once per day for one week.

[Claim 4]

The use of Claim 1, wherein 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof is to be administered orally.

[Claim 5]

Use of an effective amount of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof in the manufacture of a pharmaceutical composition for treating an LSD1-related disease in a patient in need, wherein the pharmaceutical composition is to be administered to the patient on an administration schedule of daily dosing for two weeks followed by a resting period for one week.

[Claim 6]

The use of Claim 5, wherein the administration schedule is based on a 3-week cycle,

and the cycle is performed once or repeated two or more times.

[Claim 7]

The use of Claim 5, wherein 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof is to be administered once per day for two weeks.

[Claim 8]

The use of Claim 5, wherein 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof is to be administered orally.

[Claim 9]

Use of an effective amount of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof in the manufacture of a pharmaceutical composition for treating acute myeloid leukemia (AML) in a patient in need, wherein the pharmaceutical composition is to be administered to the patient as a single agent once daily on specific days during a 28-day cycle.

[Claim 10]

The use of Claim 9, wherein 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof is to be administered daily for one week, followed by a resting period of one week.

[Claim 11]

Use of an effective amount of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof in the manufacture of a pharmaceutical composition for treating acute myeloid leukemia (AML) in a patient in need, wherein the pharmaceutical composition is to be administered to the patient as a single agent once daily on specific days during a 21-day cycle.

[Claim 12]

The use of Claim 11, wherein 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof is to be

administered daily for two weeks, followed by a resting period of one week.

[Claim 13]

Use of an effective amount of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof in the manufacture of a pharmaceutical composition for treating acute myeloid leukemia (AML) in a patient in need, wherein the pharmaceutical composition is to be administered to the patient on specific days during a 28-day cycle, in combination with all-trans retinoic acid (ATRA) twice daily.

[Claim 14]

The use of Claim 13, wherein 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof is to be administered daily for one week, followed by a resting period of one week.

[Claim 15]

Use of an effective amount of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof in the manufacture of a pharmaceutical composition for treating acute myeloid leukemia (AML) in a patient in need, wherein the pharmaceutical composition is to be administered to the patient on specific days during a 21-day cycle , in combination with all-trans retinoic acid (ATRA) twice daily.

[Claim 16]

The use of Claim 15, wherein 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof is to be administered daily for two weeks, followed by a resting period of one week.

[Claim 17]

Use of an effective amount of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof in the manufacture of a pharmaceutical composition for reducing the risk of recurrence of acute myeloid leukemia (AML) or death for a patient diagnosed with AML, wherein the

pharmaceutical composition is to be administered to the patient on an administration schedule comprising daily dosing for one week, followed by a resting period of one week.

[Claim 18]

Use of an effective amount of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof in the manufacture of a pharmaceutical composition for reducing the risk of recurrence of acute myeloid leukemia (AML) or death for a patient diagnosed with AML, wherein the pharmaceutical composition is to be administered to the patient on an administration schedule comprising daily dosing for two weeks, followed by a resting period of one week.

[Claim 19]

Use of an effective amount of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof in the manufacture of a pharmaceutical composition for reducing the risk of recurrence of acute myeloid leukemia (AML) or death for a patient diagnosed with AML, wherein the pharmaceutical composition is to be administered to the patient on an administration schedule comprising daily dosing for one week, followed by a resting period of one week, in combination with all-trans retinoic acid (ATRA) twice daily.

[Claim 20]

Use of an effective amount of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof in the manufacture of a pharmaceutical composition for reducing the risk of recurrence of acute myeloid leukemia (AML) or death for a patient diagnosed with AML, wherein the pharmaceutical composition is to be administered to the patient on an administration schedule comprising daily dosing for two weeks, followed by a resting period of one week, in combination with all-trans retinoic acid (ATRA) twice daily.

[Claim 21]

The use of any one of claims 17-20, wherein the risk of recurrence of AML or death is reduced by at least about 5%, at least about 10%, at least about 15%, at least about 20%, or at

least about 25%.

[Claim 22]

Use of a compound comprising 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof in the manufacture of a medicament for treating acute myeloid leukemia (AML), wherein the medicament is to be administered on an administration schedule comprising daily dosing for one week, followed by a resting period of one week.

[Claim 23]

Use of a compound comprising 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof in the manufacture of a medicament for treating acute myeloid leukemia (AML), wherein the medicament is to be administered on an administration schedule comprising daily dosing for two weeks, followed by a resting period of one week.

[Claim 24]

Use of a compound comprising 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof in the manufacture of a medicament for treating acute myeloid leukemia (AML), wherein the medicament is to be administered on an administration schedule comprising daily dosing for one week, followed by a resting period of one week, in combination with all-trans retinoic acid (ATRA) twice daily.

[Claim 25]

Use of a compound comprising 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof in the manufacture of a medicament for treating acute myeloid leukemia (AML), wherein the medicament is to be administered on an administration schedule comprising daily dosing for two weeks, followed by a resting period of one week, in combination with all-trans retinoic acid (ATRA) twice daily.

[Claim 26]

The use of any one of claims 13, 15, 19 and 20, wherein the pharmaceutical composition is to be administered in combination with all-trans retinoic acid (ATRA) continuously, sporadically or intermittently.